Drugs / ME3241
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07422207 | Mar 2026 → Jul 2027 expected | — | Meiji Pharma USA Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ME3241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07422207 ↗ |
| Route | Intravenous | “ME3241 Administered Intravenously” NCT07422207 ↗ |